SCHEMBL357221

SCHEMBL357221

CC1=CC(=O)c2ccccc2C1=S

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.63
MAPT P10636 5/20 0.63
CDC25B P30305 4/20 0.63
MAPK1 P28482 4/20 0.63
LMNA P02545 4/20 0.63
CDC25A P30304 3/20 0.63
IDO1 P14902 3/20 0.63
MEN1 O00255 3/20 0.63
HPGD P15428 3/20 0.63
KMT2A Q03164 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
MAOA P21397 3/20 0.63
MAOB P27338 3/20 0.63
TP53 P04637 2/20 0.63
CYP1A2 P05177 2/20 0.63
CYP3A4 P08684 2/20 0.63
HSPD1 P10809 2/20 0.63
BLM P54132 2/20 0.63
HSPE1 P61604 2/20 0.63
TST Q16762 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17861314 0.81 CDC25B (0.74) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL25970 0.77 MAPT (1.00) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL29351164 0.77 MAPT (1.00) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL1364028 0.77 MAPT (1.00) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL19356853 0.77 MAPT (1.00) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL9163371 0.76 MAPT (0.95) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL6680739 0.76 MAPT (0.95) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL9812440 0.76 MAPT (0.95) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL3411128 0.76 MAPT (0.95) ALDH1A1MAPTCDC25BMAPK1LMNA
Menadione SCHEMBL9807661 0.76 MAPT (0.95) ALDH1A1MAPTCDC25BMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118697878-B Application of CD36 as molecular marker for inhibiting lung cancer meninges metastasis and therapeutic target 广东省人民医院 2025-02-11 CN disclosed
CN-118697878-A Application of CD36 as molecular marker for inhibiting lung cancer meninges metastasis and therapeutic target 广东省人民医院 2024-09-27 CN disclosed
EP-3182129-B1 METHOD OF SCREENING A THERAPEUTIC AGENT FOR K-RAS MUTANT CANCER RAND BIO SCIENCE INC (KR) 2018-12-26 EP disclosed
EP-3182129-A1 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT RAND Bio Science Inc. (KR) 2017-06-21 EP disclosed
US-9400281-B2 Method of screening of therapeutic agents for K-Ras mutant driven cancers PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2016-07-26 US disclosed
US-20140147866-A1 COMPOUND FOR INHIBITING SNAIL-P53 BINDING AND THERAPEUTIC AGENT FOR CANCER INCLUDING THE COMPOUND AS EFFECTIVE COMPONENT THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) 2014-05-29 US disclosed
US-20120015960-A1 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) 2012-01-19 US disclosed
EP-2377849-A2 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT Pusan National University Industry-University Cooperation Foundation (KR) 2011-10-19 EP disclosed
EP-2203161-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Indiana University Research and Technology Corporation (US) 2010-07-07 EP disclosed
US-7691418-B2 Composition for inhibiting or preventing the formation of a biofilm OYSTERSHELL NV (BE) 2010-04-06 US disclosed
WO-2009042544-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-04-02 WO disclosed
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm OYSTERSHELL NV (BE) 2007-11-08 US disclosed
EP-1796656-A2 COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM Oystershell NV (BE) 2007-06-20 EP disclosed
WO-2006029893-A2 COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM OYSTERSHELL NV (BE) 2006-03-23 WO disclosed
WO-2005042442-A3 2-METHYLTHIO-1,4-NAPHTHOQUINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF UNIV MAINZ JOHANNES GUTENBERG (DE) 2005-07-07 WO disclosed
WO-2005042442-A2 2-METHYLTHIO-1,4-NAPHTHOQUINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF Johannes Gutenberg-Universität Mainz (DE) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm NQO2, NFKBIA, CROCC ALDH1A1 2205/4885MAPT 4695/4885CDC25B 2143/4885
US-20120015960-A1 CHEMICAL INHIBITOR OF P53-SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER DISEASE CONTAINING SAME AS ITS ACTIVE INGREDIENT TP53, TP53BP1, KRAS ALDH1A1 1990/4885MAPT 1592/4885CDC25B 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.